Lv41
560 积分 2023-04-10 加入
Immune responses in a mouse model of vitiligo with spontaneous epidermal de‐ and repigmentation
3小时前
已完结
The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue
3小时前
已完结
Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo
3小时前
已完结
Role of interleukin-17 in the pathogenesis of vitiligo
3小时前
已完结
The many faces of interleukin-17 in inflammatory skin diseases
4小时前
已完结
Risankizumab for Ulcerative Colitis
23天前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
23天前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
23天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
25天前
已完结
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
25天前
已完结
皖公网安备34019202002308
